Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

As Merger With Wyeth Hangs In The Balance Of Beijing's Hands, Pfizer CEO Tours China To Launch Scholarly Partnerships

This article was originally published in PharmAsia News

Executive Summary

BEIJING - With the fate of a $68-billion merger with Wyeth now being reviewed by the Chinese leadership, Pfizer Chief Executive Officer Jeff Kindler is on a five-day, whirlwind tour of the country, in part to launch a new wave of partnerships with scientists and scholars

You may also be interested in...



Pfizer's Core Leaders Outline Drive To Downsize In U.S., Europe While Expanding In BRIC Countries Including China

BEIJING - The core leaders of one of the globe's top pharmaceutical players - Pfizer Inc - told shareholders this week that they would push forward with a worldwide operation to reduce costs by downsizing in the West while ramping up sales forces in China and the other BRIC emerging markets

Pfizer's Core Leaders Outline Drive To Downsize In U.S., Europe While Expanding In BRIC Countries Including China

BEIJING - The core leaders of one of the globe's top pharmaceutical players - Pfizer Inc - told shareholders this week that they would push forward with a worldwide operation to reduce costs by downsizing in the West while ramping up sales forces in China and the other BRIC emerging markets

Eager To Counter Patent Cliff, Falling Share Price, Pfizer Forges New Partnerships Around The World, Inside China

BEIJING - The New York-headquartered Pfizer Inc. entered into an agreement with the Osaka-based Takeda Pharmaceutical to co-promote Takeda's diabetes drug Actos (pioglitazone) inside China in part because the American outfit can rely on its vastly expanded sales network here following its merger with Wyeth

Related Content

UsernamePublicRestriction

Register

WI964848

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel